Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Standard-of-care setting results of axi-cel in R/R large B-cell lymphoma

Loretta Nastoupil • 11 Sep 2020
SOHO 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel Tocilizumab
ZUMA-1

Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines results from the US Lymphoma CAR-T Consortium evaluating standard-of-care axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Loretta Nastoupil

1:10
NHL: What's hot at ASH 2023?
Loretta Nastoupil • 8 Dec 2023
2:20
Tazemetostat + lenalidomide & rituximab vs. lenalidomide & rituximab in patients with R/R FL
Loretta Nastoupil • 8 Dec 2023
1:48
TRANSCEND FL: liso-cel as 2L therapy in patients with high-risk R/R follicular lymphoma
Loretta Nastoupil • 8 Dec 2023
1:51
Optimizing immunotherapy for 3L or later R/R follicular lymphoma: liso-cel versus mosunetuzumab
Loretta Nastoupil • 8 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals